Industry urges policy on CGTs as PwC Pathfinder Study shows potential to tackle unmet medical needs

The originator biopharmaceutical industry has called for a policy on the adoption of cell and gene therapies (CGTs) by the health services as a new study shows the breakthrough treatments have the potential to tackle unmet medical needs.

The policy would emerge from a White Paper, led by the Department of Health. The industry is keen to engage in structured cross-stakeholder dialogue on a pathway for the urgent adoption of cell and gene therapies by the health services.